Explore comprehensive treatments for CIDP, including corticosteroids, plasma exchange, immunoglobulin therapy, and others.

Learn the key differences between CIDP and GBS, including causes, onset, and treatments, to ensure you get the correct ...

FY 2025 Preliminary Unaudited Total Revenue of Approximately $510--511 Million Meets or Exceeds Prior Guidance Previously Provided FY 2025 Adjusted EBITDA (1) and Adjusted Net Income (2) Guidance ...

Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); BLA Submission with ...

The Key Intravenous Immunoglobulin Companies in the market include - Takeda, Mitsubishi Tanabe Pharma, AbbVie, Prothya Biosolutions, and others. DelveInsight’s “Intravenous Immunoglobulin Market ...

A small Canadian province feared it had a mystery neurological illness on its hands. The search for answers set off a battle ...

A small Canadian province feared it had a mystery neurological illness on its hands. The search for answers set off a battle ...

Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European Data from ...

A live audio webcast of the call will be available under "Events & Webcasts" in the investor section of the Company's website, https://ir.admabiologics.com/events-webcasts. An archived webcast will be ...

Long COVID affects an estimated 65 million people worldwide and can damage the brain, heart, blood vessels, and immune system ...

Discover the latest breakthroughs in multiple myeloma treatment, including CAR T-cell therapies and promising new options for ...

Following the FDA approval of rilzabrutinib (Wayrilz; Sanofi) for immune thrombocytopenia (ITP), a rare autoimmune disorder, David Kuter, MD, DPhil, highlights the most pressing a ...